HPV-CTLs

PreclinicalBiologic

SShenzhen Geno-Immune Medical Institute

HPV-CTLs is one of 4 biologic programs targeting Human Papilloma Virus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Human Papilloma VirusRecruiting

Human Papilloma VirusPreclinical

Recruiting

Competition

Competitive Landscape

4 competitors in Human Papilloma Virus

#DrugCompanyPhaseTrials

Lenvima

Eisai

Phase 2

1 2

Keytruda

Merck & Co.

Phase 2

1 3

Gardasil9

Merck & Co.

Phase 1

1 4

HPV-CTLs

SShenzhen Geno-Immune Medical Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

PreclinicalRecruiting

Human Papilloma Virus

NCT03351855

Clinical

Trials by Indication[1]

Human Papilloma Virus1 trial

Phase I/II and Multicenter Trial of HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of Human Papilloma Virus (HPV) Infection

Recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT03351855·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HPV-CTLs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HPV-CTLs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HPV-CTLs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenzhen Geno-Immune Medical Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: SShenzhen Geno-Immune Medical Institute

HPV-CTLs

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Human Papilloma Virus1 trial

References

Drug Info

Quick Facts

Related News